olivLaw · US equity research
Rocket Pharmaceuticals, Inc. RCKT
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Rocket Pharmaceuticals develops gene therapies for rare, inherited cardiac diseases and, in 2026, obtained FDA approval for KRESLADI, its first commercial product. The sale of a rare pediatric priority review voucher brought in significant non-dilutive capital, and the company is working with the FDA to complete the Danon disease pivotal study after a 2025 clinical hold, with a runway it states extends into the second quarter of 2028 on its current plan.
At the close of 05 Nov 2026, Rocket Pharmaceuticals, Inc. (RCKT) stock was 2.44 USD (−6.70% on the day), with market capitalisation 267.3 m USD, beta 1.39, 52-week range 2.18–5.30 USD. Latest reported quarter (Q2 2026): revenue of 0 USD, net income of 123.2 m USD, diluted EPS 1.08 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 45.4
- neutral
- Bollinger (20, 2)
- 2.13 – 2.65
- in the upper half of the band · %B 0.59 · band width 22.1%
- SMA 50 / 200
- 2.89 / 3.43
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.08 / -0.13
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −1.8% | −5.9% | +4.1 pp | — |
| 3 months | −31.2% | −4.6% | −26.6 pp | — |
| 6 months | −33.7% | +0.2% | −33.9 pp | — |
| Year to date | −30.6% | +7.4% | −38.1 pp | — |
| 1 year | −26.7% | +8.2% | −34.9 pp | +15.7% |
| 3 years | −87.8% | +68.4% | −156.2 pp | +12.0% |
| 5 years | −93.2% | +56.5% | −149.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & development | 42.3 m | 37.4 m | 35.9 m | 42.7 m | 34.1 m | 29.3 m | 31.5 m | 29.5 m |
| Operating income | -69.4 m | -62.7 m | -64.4 m | -71.1 m | -52.2 m | -44.0 m | -48.5 m | -46.9 m |
| Depreciation & amortisation | 1.9 m | 1.8 m | 2.5 m | 2.0 m | 2.7 m | 1.7 m | 1.6 m | 1.6 m |
| Interest expense | 471.0 k | 473.0 k | 472.0 k | 473.0 k | 473.0 k | 473.0 k | 473.0 k | 473.0 k |
| Pre-tax income | — | — | — | -68.9 m | — | — | — | 131.8 m |
| Income tax | — | — | — | 0 | — | — | — | 8.6 m |
| Net income | -66.7 m | -60.3 m | -61.3 m | -68.9 m | -50.3 m | -42.5 m | -47.6 m | 123.2 m |
| Diluted EPS | -0.71 | -0.62 ≈ | -0.56 | -0.62 | -0.45 | -0.38 ≈ | -0.42 | 1.08 |
| Operating cash flow | -52.1 m ≈ | -46.9 m | -55.8 m | -49.0 m ≈ | -50.4 m ≈ | -34.8 m | -45.4 m | -39.6 m ≈ |
| Capex | 1.6 m ≈ | 309.0 k | 364.0 k | 50.0 k ≈ | -54.0 k ≈ | 80.0 k | 93.0 k | 8.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -74.5 m | -77.3 m | -139.7 m | -169.1 m | -221.9 m | -245.6 m | -258.7 m | -223.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -1.58 | -2.52 | -2.67 | -3.26 | -2.92 | -2.73 | -2.01 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | -55.2 m | -87.9 m | -95.2 m | -128.8 m | -186.5 m | -211.4 m | -215.6 m | -190.5 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 77.6 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 277.2 m USD
- Total assets
- 330.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 6.38x
- ROE
- -60.3%
- ROA
- -52.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | SEC (XBRL)· 26 Feb 2026verified |
| Research & development | 105.4 m | 125.5 m | 165.6 m | 186.3 m | 171.2 m | 142.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | -134.3 m | -167.2 m | -224.3 m | -259.7 m | -273.2 m | -231.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 1.1 m | 3.2 m | 3.9 m | 4.9 m | 7.2 m | 8.9 m | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | -133.2 m ≈ | -164.0 m ≈ | -220.4 m ≈ | -254.8 m ≈ | -266.0 m ≈ | -222.8 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Interest expense | 7.0 m | 3.0 m | 1.9 m | 1.9 m | 1.9 m | 1.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Pre-tax income | — | — | — | — | -258.7 m | -223.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | — | — | — | 0 | 0 | 0 | SEC (XBRL)· 26 Feb 2026verified |
| Net income | -139.7 m | -169.1 m | -221.9 m | -245.6 m | -258.7 m | -223.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | -2.52 | -2.67 | -3.26 | -2.92 | -2.73 | -2.01 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 55.4 m | 63.2 m | 68.1 m | 84.0 m | 94.8 m | 111.1 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 297.1 m | 232.7 m | 140.5 m | 55.9 m | 163.6 m | 77.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 487.3 m | 392.1 m | 364.1 m | 378.2 m | 378.2 m | 192.7 m | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 19.2 m | 22.3 m | 29.0 m | 39.2 m | 36.8 m | 28.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Goodwill | 30.8 m | 30.8 m | 39.2 m | 39.2 m | 39.2 m | 39.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Intangibles (excl. goodwill) | — | 0 | 25.7 m | 25.2 m | 25.2 m | 25.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 590.8 m | 497.0 m | 551.8 m | 566.3 m | 527.7 m | 330.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 25.5 m | 19.6 m | 36.7 m | 45.8 m | 37.8 m | 27.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 32.6 m | 22.2 m | 39.2 m | 48.5 m | 40.7 m | 30.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 87.3 m | 42.3 m | 62.1 m | 73.8 m | 64.5 m | 53.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 503.5 m † | 454.7 m † | 489.7 m † | 492.6 m † | 463.2 m † | 277.2 m † | SEC (XBRL)· 26 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -74.6 m | -121.2 m | -178.1 m | -194.9 m | -209.7 m | -190.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 20.6 m | 7.6 m | 8.4 m | 16.4 m | 5.9 m | 440.0 k | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | -95.2 m ≈ | -128.8 m ≈ | -186.5 m ≈ | -211.4 m ≈ | -215.6 m ≈ | -190.5 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -96.6 m | 18.9 m | -69.3 m | -98.1 m | 131.7 m | 103.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | 283.0 m | 37.7 m | 155.3 m | 208.4 m | 185.7 m | 148.0 k | SEC (XBRL)· 26 Feb 2026verified |
| Share repurchases | 72.0 k | 0 | — | — | — | — | SEC (XBRL)· 28 Feb 2022verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 267.3 m USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -101.3x | 0 (on a fixed band) | 33% |
| Current ratio · Balance sheet | 9.2x | 100 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -63.7% | 0 (on a fixed band) | 44% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Rocket Pharmaceuticals, Inc. (RCKT). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2025; ROE -4.8%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 9.2x
What contradicts it
- Interest coverage: -101.3x
- FCF yield: -63.7%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,283.9 bn | 44.3 | 86.1% | 31.9% | +44.7% | +27% / +131% |
| JNJJohnson & Johnson | 655.6 bn | 41.3 | 20.0% | 16.2% | +6.0% | +32% / +76% |
| ONCBeone Medicines Ltd. | 575.0 bn | 640.9 | 18.4% | 13.9% | +40.2% | +14% / +107% |
| ABBVAbbVie Inc. | 509.5 bn | 49.6 | — | 15.7% | +8.6% | +27% / +102% |
| MRKMerck & Co., Inc. | 362.2 bn | 151.2 | 5.1% | 3.6% | +1.3% | +40% / +43% |
| ABTAbbott Laboratories | 196.7 bn | 42.3 | 9.2% | 9.7% | +5.7% | −12% / +9% |
| PFEPfizer Inc | 170.3 bn | 42.6 | 4.4% | 6.3% | −1.6% | +16% / −2% |
| VRTXVertex Pharmaceuticals Inc | 137.5 bn | 34.9 | 20.8% | 30.7% | +8.9% | +25% / +53% |
| BMYBristol-Myers Squibb Company | 129.0 bn | 14.0 | 44.1% | 18.5% | −0.2% | +28% / +28% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.3 | 6.6% | 3.6% | +4.3% | +55% / +325% |
| ZTSZoetis Inc. | 33.4 bn | 13.8 | 57.6% | 26.4% | +2.3% | −36% / −54% |
| ROIVRoivant Sciences Ltd. | 26.5 bn | — | -6.2% | -3,535.0% | −71.6% | +76% / +283% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 24.1 bn | 21.3 | 19.1% | 38.6% | +10.6% | +16% / +136% |
| INSMInsmed Inc | 23.9 bn | — | -72.5% | -39.9% | +66.7% | −48% / +335% |
| VTRSViatris Inc. | 21.7 bn | — | -24.3% | -23.9% | −3.0% | +77% / +107% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.0 bn | 7.9 | 126.6% | 52.8% | +65.2% | −65% / −7% |
| RDYDr. Reddy’s Laboratories Limited | 12.1 bn | 18.4 | 17.0% | 17.4% | +13.8% | +3% / +4% |
| PRAXPraxis Precision Medicines, Inc. | 7.3 bn | — | -38.9% | — | −100.0% | +34% / +1,343% |
| INDVIndivior Pharmaceuticals, Inc. | 4.3 bn | 10.2 | — | 32.8% | +4.3% | +8% / +114% |
| ACADAcadia Pharmaceuticals Inc. | 3.7 bn | 10.1 | 31.4% | 30.1% | +11.9% | −15% / −5% |
| ARQTArcutis Biotherapeutics, Inc. | 3.4 bn | 125.2 | 14.9% | 5.9% | +91.3% | −12% / +1,367% |
| CYRXCryoport, Inc. | 813.7 m | — | -8.3% | -21.5% | +12.4% | +67% / +14% |
| AVTXAvalo Therapeutics, Inc. | 383.4 m | — | -33.6% | -150,259.3% | −86.6% | −65% / −61% |
| RCKTRocket Pharmaceuticals, Inc. | 267.3 m | — | -4.8% | — | unavailable | −27% / −88% |
1- and 3-year price returns: for RCKT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Rocket Pharmaceuticals develops gene therapies for rare, inherited cardiac diseases and, in 2026, obtained FDA approval for KRESLADI, its first commercial product. The sale of a rare pediatric priority review voucher brought in significant non-dilutive capital, and the company is working with the FDA to complete the Danon disease pivotal study after a 2025 clinical hold, with a runway it states extends into the second quarter of 2028 on its current plan 123.
SWOT
Strengths
Weaknesses
- The company generated no product sales revenue until KRESLADI's approval, and annual net losses have been significant 1.
- Profit in the second quarter of 2026 is largely due to a non-recurring voucher sale rather than a stable operating business 3.
- The portfolio has narrowed, concentrating risk on a few candidates, and workforce reductions could affect execution 1.
Opportunities
- If the Danon pivotal study progresses as planned, the company could seek approval for a patient population estimated in the tens of thousands 12.
- KRESLADI's commercial launch could produce first product revenue and experience that may help the cardiac programs 3.
- If the FDA accepts a pivotal design for PKP2-ACM, the company could expand its cardiac portfolio into an area without disease-modifying therapies 23.
Threats
- The serious events in the 2025 Danon study show the safety risk of the platform, and a new issue could delay or halt the program 13.
- Securities class actions and derivative suits filed in 2025 could generate costs and divert management, with uncertain outcomes 1.
- If tax rules or voucher legislation change, the value of future funding and the use of tax loss carryforwards could be affected 1.
Risks
- Danon therapy safetyhigh
Serious events in May 2025, including a death, led to a suspension and a resumed study at a lower dose; any new event could reignite the hold 13.
- Dependence on a few candidateshigh
After the reorganization the company relies on a small number of programs, so failure of one could materially affect its outlook 1.
- Funding runwaymedium
The company states its runway extends into the second quarter of 2028, but future spending could rise if studies expand 3.
- Securities litigationmedium
Class actions and derivative suits from 2025 are pending, outcomes are uncertain, and they could generate significant costs 1.
- KRESLADI commercial executionlow
The launch depends on specialized centers and patient identification, and delays could postpone the expected revenue 23.
Investment thesis
What would need to be true (bull case)
- If the cardiac gene therapies confirm clinical benefit in pivotal studies, the company could become the first to treat the genetic cause of rare cardiomyopathies, a significant advantage 12.
- KRESLADI's approval and the voucher sale strengthened the financial position and show the company can bring a complex product through approval 23.
- An integrated AAV manufacturing platform could reduce dependence on third parties and speed up other programs if they advance 12.
What would break the thesis
- The company had to reorganize, cut staff and drop programs, suggesting its resources are limited relative to its ambitions 12.
- Recent profit reflects a non-recurring voucher sale, and without product revenue or further asset sales, operating losses could return 3.
- If the FDA requires additional data or design changes for the Danon or PKP2-ACM studies, timelines and costs could rise significantly 3.
What to watch
- FDA alignment on the Danon disease regulatory path and the number of patients neededsecond half of 2026
- Update on the pivotal study design for PKP2-ACMsecond half of 2026
- Start of patient onboarding and commercial availability of KRESLADIQ4 2026
- Third-quarter financial results and trend in operating expensesnext 10-Q
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company that develops, manufactures and could commercialize gene therapies for rare, often fatal diseases with high unmet medical need 1. Its platform uses AAV and lentiviral viral vectors, and its current strategy focuses on rare cardiovascular programs, mainly Danon disease (RP-A501), PKP2-ACM (RP-A601) and BAG3-DCM (RP-A701) 12. The company operates an AAV cGMP facility in Cranbury, New Jersey, and completed a 2025 reorganization that cut the workforce by about 30% and concentrated resources on the cardiovascular platform and KRESLADI 12.
Financially, Rocket had until recently generated no product revenue, reported net losses and carried a large accumulated deficit, so later development has depended on external funding 1. In the quarter ended June 30, 2026 the picture changed temporarily: the voucher sale generated significant other income and the company reported net income, though this is a non-recurring item 3. For KRESLADI, the company expects commercial availability and the start of patient onboarding in the fourth quarter of 2026, with a focused commercial approach built on specialized treatment centers 3.
The strategy emphasizes monogenic diseases with direct on-target mechanisms and indications large enough to justify investment, aiming to be first or best in class 12. If data are favorable, the company plans to submit BLAs for certain clinical programs and to extend its platform to compatible indications 2.
Segments
Cardiac gene therapy (AAV)
This is the priority segment after the 2025 reorganization and includes RP-A501 for Danon disease, RP-A601 for PKP2-ACM and RP-A701 for BAG3-DCM 123. For Danon disease, the company reported that the first three patients dosed under the modified protocol showed no thrombotic microangiopathy or capillary leak syndrome, and the next step depends on alignment with the FDA 3.
KRESLADI (ex vivo LV therapy)
KRESLADI is the gene therapy for severe LAD-I, an ultra-rare pediatric immunodeficiency, and the company's first approved product, granted accelerated approval in March 2026 23. The company said it does not expect material revenue in the near term because of the very small patient population, with commercial availability planned for the fourth quarter of 2026 23.
Market context
The company targets rare inherited cardiac diseases with estimated prevalence in the tens of thousands of patients in the U.S. and Europe, for example 15,000 to 30,000 for Danon disease and 50,000 for PKP2-ACM 1. Existing therapies are largely symptomatic and cardiac transplant is available to only a minority of patients, leaving room for therapies that could modify the disease course 1.
Demand for rare gene therapies depends on regulatory acceptance, pricing and reimbursement, and manufacturing capacity; for KRESLADI the market is so narrow that revenue will depend on the number of specialized centers and identified patients 23.
Trends
- Regulatory approval pathway for gene therapiestailwind
The FDA approved KRESLADI through an accelerated pathway, which shows a regulatory route exists for gene therapies and could support the company's other programs 13.
- Danon study hold and safety riskheadwind
Serious adverse events in 2025 led to a pause and a clinical hold, and resumption depends on FDA alignment on the recalibrated dose and patient numbers, which could delay the timeline 13.
- Priority review vouchers as a funding sourcemixed
The sale of a rare pediatric voucher provided non-dilutive capital, but this mechanism depends on Congressional renewal of the program, so it is not assured for the future 23.
- Pressure to cut research and restructuring costsmixed
Headcount and spending reductions lowered operating costs but could affect the ability to attract and keep specialized staff as programs advance 12.
Competitive position
The sources do not identify named competitors, so the competitive analysis is limited to the fact that other developers could pursue the same rare cardiac indications, while existing options include symptomatic drugs, implantable defibrillators and transplantation 1.
The company cites its integrated AAV cGMP manufacturing and its experience with drug approvals as advantages, but these must be weighed against developers that may have larger resources 12.
- Symptomatic standard of care (beta blockers, antiarrhythmics, ICDs)
Standard treatments for arrhythmia and cardiomyopathy do not modify the disease course, leaving room for therapies that address the genetic cause 1.
- Cardiac transplantation
It is the only curative option for advanced cardiomyopathy but is available to a minority of patients and carries significant morbidity 1.
- Other cardiac gene therapy developers
The sources do not name them; a potential competitor could target the same indications or use similar AAV mechanisms.
- Alternatives for LAD-I
Hematopoietic stem cell transplantation from a suitable donor remains the alternative for eligible patients, per the KRESLADI indication description 2.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Chinese space firm builds wooden rocket nose cone for cheaper, frequent launchesSouth China Morning Post — China · 06 Nov 2026 · EN
- Blue Origin pushes New Glenn rocket launch to January, sources sayCNA (Channel NewsAsia) · 05 Nov 2026 · EN
- Blue Origin delays New Glenn rocket launch into January, FT reportsCNA (Channel NewsAsia) · 05 Nov 2026 · EN
- Blue Origin delays New Glenn rocket launch into January, sources sayCNA (Channel NewsAsia) · 05 Nov 2026 · EN
- Hanwha Aerospace breaks ground on Chunmoo rocket plant in PolandKorea Times — Business · 05 Nov 2026 · EN
- Hanwha Aerospace breaks ground on Chunmoo rocket plant in PolandYonhap News (KR, EN) · 05 Nov 2026 · EN
- 🇷🇺 🇺🇦 ⚡️ — Video footage taken immediately after a rocket strike hit police stat…Telegram — Intel Slava Z (pro-RU OSINT EN) · 03 Nov 2026 · EN
- The new CEO of the European rocket giantDefence24 (PL, EN) · 02 Nov 2026 · EN
- Ukrainian Navy destroys six Russian aircraft, ten multiple launch rocket systems in OctoberUkrinform (UA, EN) · 02 Nov 2026 · EN
- Zelensky confirms attack on Russian rocket fuel factory, missile launcher systemKyiv Independent (UA, EN) · 01 Nov 2026 · EN
- Ukraine hits plant producing fuel for Russian multiple-launch rocket systems in Rostov Oblast, military saysKyiv Independent (UA, EN) · 31 Oct 2026 · EN
- Ukrainian forces strike rocket fuel plant in Russia's Rostov regionUkrinform (UA, EN) · 31 Oct 2026 · EN
- Drones and Neptune Missiles Strike Kamensky Rocket Fuel PlantKyiv Post · 31 Oct 2026 · EN
- New gel fuel could make rocket and satellite propulsion easier to controlPhys.org · 31 Oct 2026 · EN
- Ukraine strikes Russian rocket fuel plant with Neptune missiles and drones – General StaffUkrainska Pravda (UA, EN) · 31 Oct 2026 · EN
- (LEAD) N. Korea showcases 'Sniper' rocket launcher in weapons demonstrationYonhap News (KR, EN) · 30 Oct 2026 · EN
- N. Korea reports weapons demonstration featuring cruise missiles, rocket launchers, dronesYonhap News (KR, EN) · 29 Oct 2026 · EN
- MuRay raises €7.1M to inspect rocket engines and turbines beyond X-ray limitsTech.eu · 29 Oct 2026 · EN
- Exclusive: Deeptech startup MuRay raises €7.1m to see inside rocket enginesSifted (EU startups) · 29 Oct 2026 · EN
- Chinese scientists create powerful catalyst to turn air on Mars into rocket fuelSouth China Morning Post — China · 27 Oct 2026 · EN
SEC filings
- Current report06 Oct 2026Material agreement · Creation of a direct financial obligation · Item 3.02 · Regulation FD disclosure · Financial statements and exhibits
- Current report15 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report27 Aug 2026Departure or appointment of officers
- Current report10 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report10 Aug 2026
- Current report03 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Current report30 Jun 2026Departure or appointment of officers
- Current report12 Jun 2026Acquisition or disposition of assets · Regulation FD disclosure · Financial statements and exhibits
- Current report21 May 2026Shareholder vote
- Current report07 May 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Rocket Pharmaceuticals, Inc. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Rocket Pharmaceuticals, Inc. · 10 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Rocket Pharmaceuticals, Inc. · 10 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.